RU2017115651A - Фармацевтические составы для пероральной доставки пептидных или белковых лекарственных средств - Google Patents

Фармацевтические составы для пероральной доставки пептидных или белковых лекарственных средств Download PDF

Info

Publication number
RU2017115651A
RU2017115651A RU2017115651A RU2017115651A RU2017115651A RU 2017115651 A RU2017115651 A RU 2017115651A RU 2017115651 A RU2017115651 A RU 2017115651A RU 2017115651 A RU2017115651 A RU 2017115651A RU 2017115651 A RU2017115651 A RU 2017115651A
Authority
RU
Russia
Prior art keywords
sodium
acid
decanoyl
dodecanoyl
capric
Prior art date
Application number
RU2017115651A
Other languages
English (en)
Russian (ru)
Inventor
Флориан ФЕГЕР
Original Assignee
Ципрумед Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51751911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2017115651(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ципрумед Гмбх filed Critical Ципрумед Гмбх
Publication of RU2017115651A publication Critical patent/RU2017115651A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2017115651A 2014-10-07 2015-10-07 Фармацевтические составы для пероральной доставки пептидных или белковых лекарственных средств RU2017115651A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14187885.0 2014-10-07
EP14187885.0A EP3006045B3 (en) 2014-10-07 2014-10-07 Pharmaceutical formulations for the oral delivery of peptide or protein drugs
PCT/EP2015/073196 WO2016055550A1 (en) 2014-10-07 2015-10-07 Pharmaceutical formulations for the oral delivery of peptide or protein drugs

Publications (1)

Publication Number Publication Date
RU2017115651A true RU2017115651A (ru) 2018-11-20

Family

ID=51751911

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017115651A RU2017115651A (ru) 2014-10-07 2015-10-07 Фармацевтические составы для пероральной доставки пептидных или белковых лекарственных средств

Country Status (16)

Country Link
US (1) US20170304195A1 (https=)
EP (2) EP3006045B3 (https=)
JP (1) JP2017531665A (https=)
KR (1) KR20170061140A (https=)
CN (1) CN106794252A (https=)
AU (1) AU2015330016A1 (https=)
BR (1) BR112017006957A2 (https=)
CA (1) CA2960334A1 (https=)
DK (1) DK3006045T3 (https=)
ES (1) ES2630106T3 (https=)
IL (1) IL251462A0 (https=)
MX (1) MX2017004592A (https=)
RU (1) RU2017115651A (https=)
SG (1) SG11201702813VA (https=)
WO (1) WO2016055550A1 (https=)
ZA (1) ZA201701719B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
US10568937B2 (en) * 2016-04-18 2020-02-25 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
JP2019529506A (ja) * 2016-09-29 2019-10-17 アレコル リミテッド 新規の製剤
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
SG10201609137PA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Gamma-polyglutamic acid and zinc compositions
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CN109381695A (zh) * 2017-08-09 2019-02-26 武汉武药科技有限公司 一种门冬氨酸帕瑞肽注射液及其制备方法和用途
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
TWI751379B (zh) 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
JP7005050B2 (ja) * 2017-10-20 2022-01-21 ノブメタファーマ カンパニー リミテッド 亜鉛塩、シクロ-ヒスプロおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物
CN108079280B (zh) * 2017-12-30 2021-06-04 陕西慧康生物科技有限责任公司 治疗ⅱ型糖尿病的艾塞那肽滴鼻剂
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
EP3886814B1 (en) 2018-11-26 2025-02-19 The Procter & Gamble Company Solid pharmaceutical preparation containing lipoic acid and use thereof
CN110251662B (zh) * 2018-12-12 2023-01-31 福州市台江区希吉亚健康科技有限公司 一种具有减肥作用的药物
CN110251661B (zh) * 2018-12-12 2022-09-16 福州市台江区希吉亚健康科技有限公司 一种用于治疗糖尿病或者减肥的药物制剂
KR102327750B1 (ko) * 2018-12-19 2021-11-18 대화제약 주식회사 Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물
KR20210137373A (ko) * 2019-03-08 2021-11-17 안야 바이오팜 인코포레이티드 부갑상샘 호르몬 유사체의 경구 제제 및 치료
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
CN112057619A (zh) * 2019-06-10 2020-12-11 苏州兰鼎生物制药有限公司 一种具有降血糖作用的药物组合物
CN112138148B (zh) * 2019-06-10 2024-04-09 苏州兰鼎生物制药有限公司 一种生长激素或其类似物的口服药物组合物
WO2020257260A1 (en) 2019-06-17 2020-12-24 Massachusetts Institute Of Technology Formulation of peptide loaded liposomes and related applications
AU2020334128B2 (en) * 2019-08-21 2025-10-23 Brain Chemistry Labs Compositions comprising a metal and L-serine, and uses thereof
KR102216578B1 (ko) * 2019-09-05 2021-02-17 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 경구용 약학 조성물 및 이의 제조방법
CN114364372A (zh) * 2019-09-09 2022-04-15 株式会社泰俊制药 包含环孢菌素和薄荷醇的纳米乳液眼用组合物及其制备方法
CN112972658B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种生长激素或其类似物的口服药物组合物
CN113509544B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种具有降血糖作用的药物组合物
CN112972692A (zh) * 2019-12-14 2021-06-18 苏州兰鼎生物制药有限公司 一种促进肠吸收的药物组合物
CN112972650B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种生长抑素或其类似物的口服药物组合物
CN112972656B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种胰高血糖素样肽-2或其类似物的口服药物组合物
CN112972659A (zh) * 2019-12-14 2021-06-18 苏州兰鼎生物制药有限公司 一种特立帕肽或阿巴洛肽的口服药物组合物
CN113171446B (zh) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
CN116262134A (zh) * 2021-12-15 2023-06-16 联邦生物科技(珠海横琴)有限公司 一种稳定的多剂量给药的glp-1受体激动剂的制剂及其制备方法和应用
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
KR102492241B1 (ko) * 2022-02-25 2023-01-30 전남대학교산학협력단 Kitenin의 이량체 형성을 저해하는 펩타이드 및 이의 용도
CN120129529A (zh) * 2022-04-29 2025-06-10 鹏跃医药科技有限公司 用于鼻內給药的索马鲁肽及其盐的药物組合物
CN115161253B (zh) * 2022-05-30 2022-12-02 微康益生菌(苏州)股份有限公司 一种保持细胞结构完整性的益生菌灭活方法及其应用
EP4299071A1 (en) * 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
CN119907661A (zh) * 2022-07-05 2025-04-29 G2G生物公司 含有司美格鲁肽或其药学上可接受的盐的缓释微球制剂及其制备方法
KR102844771B1 (ko) * 2022-07-22 2025-08-12 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법
CN116271064A (zh) * 2022-09-09 2023-06-23 中山大学·深圳 一种促进利拉鲁肽安全渗透肠细胞的辅料组合物
WO2024077409A1 (en) * 2022-10-09 2024-04-18 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
KR102590243B1 (ko) * 2023-03-13 2023-10-20 주식회사 에코월드팜 수면장애 개선을 위한 l-트립토판 및 키토산을 포함하는 조성물
EP4701625A2 (en) 2023-04-26 2026-03-04 Vivtex Corporation Formulation of therapeutic agents for improved permeation
WO2025037993A1 (en) * 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents
CN119454605B (zh) * 2023-11-30 2025-12-19 深圳奥礼生物科技有限公司 一种实现多肽口服吸收的组合物
CN118001411A (zh) * 2024-04-09 2024-05-10 深圳奥礼生物科技有限公司 一种肠道吸收组合物
CN118105468B (zh) * 2024-04-23 2024-07-16 长春生物制品研究所有限责任公司 重组人干扰素α2a栓及制备方法
US12544349B1 (en) 2024-12-30 2026-02-10 Adocia Compositions comprising pemvidutide and an acylated amino acid

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ N末端修飾glp−1誘導体
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するglp−1のglp−1誘導体及びエキセンジン
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US20020009490A1 (en) * 1999-12-22 2002-01-24 Benkendorfer Travis R. Antiviral therapeutic composition and treatment
US20010012829A1 (en) * 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
US20030017195A1 (en) 2001-07-20 2003-01-23 Samir Mitragotri Method for oral drug delivery
BR122019021416A2 (https=) 2003-09-19 2019-12-21
AU2004290983A1 (en) * 2003-11-19 2005-06-02 Vecta Ltd. Methods and compositions for the treatment of Helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
CN101115769A (zh) * 2004-05-19 2008-01-30 马克西根公司 干扰素-α多肽和偶联物
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
RU2527893C2 (ru) 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
EP1781257B1 (en) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP5066448B2 (ja) * 2004-09-03 2012-11-07 協和発酵バイオ株式会社 口内炎の予防または治療のための組成物および方法
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006082245A1 (en) 2005-02-07 2006-08-10 Novo Nordisk A/S Pharmaceutical preparations comprising insulin, zinc ions and a zinc-binding ligand
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
US7618669B2 (en) * 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
WO2007029238A2 (en) 2005-09-06 2007-03-15 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
CN101309668A (zh) * 2005-11-30 2008-11-19 健乐克斯医药公司 经口吸收的药物制剂和用药方法
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
PE20110543A1 (es) * 2008-08-15 2011-08-04 Ironwood Pharmaceuticals Inc Formulacion solida oral que comprende linaclotida, cation de calcio y leucina
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
JP6016234B2 (ja) 2009-09-30 2016-10-26 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー ビタミンb部分構造を持つ粘膜付着性ポリマー
US20110311621A1 (en) * 2010-03-16 2011-12-22 Paul Salama Pharmaceutical compositions and methods of delvery
CN102970864A (zh) 2010-04-21 2013-03-13 那挪玛加医药有限公司 纳米颗粒药物组合物
MX2012012943A (es) 2010-05-10 2012-11-29 Novo Nordisk As Proceso para preparacion de complejos de insulina-cinc.
TW201202178A (en) * 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
SI2651398T1 (en) * 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
WO2012098187A1 (en) * 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 compositions
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法
EP2696847A1 (en) 2011-04-14 2014-02-19 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
EP2717858B1 (en) * 2011-06-10 2018-08-08 Aquestive Therapeutics, Inc. Combination peptide-nanoparticles and delivery systems incorporating same
US20130004590A1 (en) 2011-06-28 2013-01-03 Lin Connie B Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation
CN111053918A (zh) * 2011-09-05 2020-04-24 韩美科学株式会社 一种包含干扰素α-缀合物的抗癌用药物组合物
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
US20150174076A1 (en) 2012-06-14 2015-06-25 Entrega, Inc. Mucoadhesive devices for delivery of active agents
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
CN103948915B (zh) * 2014-05-05 2016-06-22 德立唯(北京)生物科技有限公司 一种能够提高稳定性和口服疗效的用于预防血栓形成和溶栓的纳豆激酶组合物
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos

Also Published As

Publication number Publication date
EP3204045A1 (en) 2017-08-16
CA2960334A1 (en) 2016-04-14
AU2015330016A1 (en) 2017-04-20
CN106794252A (zh) 2017-05-31
DK3006045T3 (en) 2017-07-17
MX2017004592A (es) 2017-07-10
US20170304195A1 (en) 2017-10-26
WO2016055550A1 (en) 2016-04-14
EP3006045B3 (en) 2021-03-17
KR20170061140A (ko) 2017-06-02
EP3204045B1 (en) 2018-12-05
JP2017531665A (ja) 2017-10-26
SG11201702813VA (en) 2017-05-30
ZA201701719B (en) 2018-05-30
EP3006045B1 (en) 2017-04-12
BR112017006957A2 (pt) 2017-12-19
IL251462A0 (en) 2017-05-29
ES2630106T3 (es) 2017-08-18
EP3006045A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
RU2017115651A (ru) Фармацевтические составы для пероральной доставки пептидных или белковых лекарственных средств
JP2025179167A5 (https=)
JP2017531665A5 (https=)
JP2021520391A5 (https=)
JP2018529749A5 (https=)
US10905744B2 (en) Pharmaceutical formulations for the oral delivery of peptide drugs
US12208118B2 (en) Pharmaceutical compositions for delivery of peptide
WO2018065634A1 (en) Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
US9445992B2 (en) Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion
CN111971027A (zh) 副甲状腺素类似物的口服制剂及治疗
EP3419649B1 (en) Stable pharmaceutical compositions comprising insulin glargine and insulin aspart and methods of preparation thereof
KR102954604B1 (ko) 인간 부갑상선 호르몬(pth)의 제형 및 그 제조 방법
NZ760995B2 (en) Pharmaceutical compositions for delivery of peptide
WO2021195877A1 (en) Formulations of human parathyroid hormone (pth) and methods for producing same